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| INTRODUCTION
Oral anticoagulants are the treatment of choice for prevention of stroke in most patients with nonvalvular atrial fibrillation and for treatment and prevention of venous thromboembolism. Historically, vitamin K antagonists were the only oral anticoagulants for clinical use. Due to the unpredictable pharmacokinetics, regular monitoring of the anticoagulation effect using the international normalized ratio (INR) is required to ensure safe use. Due to its long half-life, the anticoagulant effect persists long after interruption. Although administration of vitamin K reduces the time to INR normalization, this effect requires many hours. Therefore, complexes of clotting factors (prothrombin complex concentrate; PCC) have been used to quickly replenish the coagulation system and urgently restore coagulation in patients treated with vitamin K antagonists.
Essentials
• There is scant data on surgery shortly after intake of rivaroxaban.
• We performed neurosurgery using high dose PCCs and tranexamic acid.
• Intraoperative haemostasis was good and no transfusion was needed.
• There was no delayed postoperative haemotoma or thromboembolic complication.
In the recent decade, other direct oral anticoagulant drugs (DOACs) were developed. Because they can be used without need for monitoring, the tests that measure their anticoagulant effect are less routinely 
| DISCUSSION
Intracranial and intraspinal hemorrhage is a rare but devastating complication of anticoagulation therapy. Although DOACs significantly In our patient, the prolonged prothrombin time was compatible with the recent intake of rivaroxaban, which was confirmed by the rivaroxaban level using an anti-factor Xa-chromogenic assay. Of note, specific assays may not be available at any hospital and at any time.
This case illustrates that the rapid availability of specific coagulation tests can be helpful as a guidance in challenging cases. However, in the absence of such information, time since last dose and renal function can help to approximate the residual anticoagulant activity. In this case, the indication for surgery was present a couple of hours after last intake of rivaroxaban.
In vitro and preclinical studies have shown that the use of prothrombin complex concentrate, which contain coagulation factor II, VII, IX, and X, can counteract the effect of DOACs, especially when administered in a high dose (50 U/kg). PCCs were effective in reducing bleeding in animal models of severe trauma during NOAC treatment. 12 In healthy volunteers who received rivaroxaban or apixaban, PCCs (50 U/kg) reversed the effects on coagulation tests and biopsyinduced bleeding. 13, 14 Therefore, PCCs are recommended as a prohemostatic agent in patients treated with a factor Xa inhibitor who present with severe or life-threatening bleeds not responding to conservative measures. 15 For patients treated with the thrombin inhibitor dabigatran, the specific reversal agent idarucizumab can rapidly and completely reverse the anticoagulant effect. Idarucizumab is approved by the Food and Drug Administration and European Medicines Agency in patients with recent intake of dabigatran requiring urgent surgery or presenting with life-threatening bleeding.
This patient, treated with rivaroxaban, presented both with an acute bleeding complication in a critical organ and with the need for an urgent intervention. Diagnosis of the bleeding and indication for surgery was made at the time of expected peak rivaroxaban levels.
Administration of PCCs is therefore recommended. In patients without a bleeding but requiring an urgent procedure, an analogous strategy has been proposed ( Table 1 ).
In conclusion, we performed an urgent laminectomy and durotomy with evacuation of the subdural hematoma after administration of PCCs and tranexamic acid less than 5 hours after rivaroxaban intake. Pre-and postoperative hemostasis was assessed as normal. Early surgery after administration of rivaroxaban seems feasible in case of an emergency indication, but more experience is necessary on the hemostatic effects and the thrombotic risk of such strategy. An important inherent limitation of case reports is that we cannot compare outcome of the chosen treatment with alternatives, such as delaying surgery or using other measures of hemostatic support. Therefore, this case by itself cannot compare the relative efficacy or safety of this approach. Nevertheless, the case illustrates that clotting factor concentrates can be considered as an option in patients requiring urgent surgery at peak anticoagulant levels. It also illustrates the importance of interdisciplinary communication in complex patients.
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